Homocysteine: role and implications in atherosclerosis
Related Experiment Video
Updated: Aug 11, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Sasidhar Guthikonda1, William G Haynes
1Department of Cardiology, Bayor College of Medicine, Houston, TX 77584, USA. guthikon@bcm.tmc.edu
Insights
Hyperhomocysteinemia, linked to B-vitamin deficiencies, accelerates atherosclerosis by increasing oxidative stress and thrombosis. Supplementing folic acid, B6, and B12 can effectively lower homocysteine levels.
Area of Science:
- Cardiovascular Science
- Metabolic Disorders
- Nutritional Biochemistry
Background:
- Hyperhomocysteinemia is a condition characterized by elevated levels of homocysteine in the blood.
- It is frequently associated with deficiencies in B vitamins (folic acid, B6, B12), genetic factors, certain medications, and kidney dysfunction.
- Elevated homocysteine contributes to atherosclerosis via increased oxidative stress, endothelial dysfunction, and promotion of thrombosis.
Purpose of the Study:
- To review the role of hyperhomocysteinemia in atherosclerosis.
- To discuss the causes and consequences of elevated homocysteine levels.
- To outline appropriate diagnostic and therapeutic strategies for hyperhomocysteinemia.
Main Methods:
- Review of prospective studies and established literature on homocysteine and cardiovascular disease.
- Analysis of mechanisms by which homocysteine impacts vascular health.
- Evaluation of current treatment approaches, including vitamin supplementation.
Main Results:
- Prospective studies indicate that elevated plasma homocysteine levels double the risk of cardiovascular disease and moderately increase cerebrovascular disease risk.
- Identification of hyperhomocysteinemia is crucial in patients with unexplained or progressive atherosclerosis.
- Vitamin supplementation (folic acid, B6, B12) is the primary treatment, with betaine and 5-methyl tetrahydro-folate also showing efficacy.
Conclusions:
- Hyperhomocysteinemia is a significant risk factor for atherosclerosis and cardiovascular events.
- Prompt identification and treatment with B vitamins are recommended for affected patients.
- Further randomized outcome trials are needed to guide treatment for moderately elevated homocysteine in individuals without existing atherosclerosis.
Abstract:
Hyperhomocysteinemia promotes atherosclerosis and is most commonly caused by B-vitamin deficiencies, especially folic acid, B(6), and B(12); genetic disorders; certain drugs; and renal impairment. Elevated homocysteine promotes atherosclerosis through increased oxidant stress, impaired endothelial function, and induction of thrombosis. Prospective studies have shown that elevated plasma homocysteine concentrations increase risk of cardiovascular disease by twofold and risk of cerebrovascular disease to a lesser degree. Hyperhomocysteinemia should be identified in patients with progressive or unexplained atherosclerosis and treated appropriately. Treatment of hyperhomocysteinemia is primarily through vitamin supplementation; folic acid and vitamins B(6) and B(12) are the mainstay of therapy. Betaine and 5-methyl tetrahydro-folate are also effective in lowering homocysteine levels. Treatment of moderately elevated plasma homocysteine in patients without atherosclerosis should be deferred until the completion of randomized outcome trials.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology